Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Assets (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Non-Current Assets for 4 consecutive years, with $319.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 691.35% to $319.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $832.1 million through Dec 2025, up 393.04% year-over-year, with the annual reading at $319.6 million for FY2025, 691.35% up from the prior year.
  • Non-Current Assets for Q4 2025 was $319.6 million at Centessa Pharmaceuticals, up from $140.6 million in the prior quarter.
  • The five-year high for Non-Current Assets was $319.6 million in Q4 2025, with the low at $993000.0 in Q1 2022.
  • Average Non-Current Assets over 4 years is $72.8 million, with a median of $42.9 million recorded in 2023.
  • The sharpest move saw Non-Current Assets surged 2637.15% in 2023, then decreased 10.55% in 2024.
  • Over 4 years, Non-Current Assets stood at $6.6 million in 2022, then surged by 588.32% to $45.2 million in 2023, then decreased by 10.55% to $40.4 million in 2024, then soared by 691.35% to $319.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $319.6 million, $140.6 million, and $191.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.